Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average […]

Related Keywords

United States , Piper Sandler , Tobin Schilke , Nasdaq , Needham Company , Principal Financial Group Inc , Goldman Sachs Group , Barclays , Securities Exchange Commission , Revance Therapeutics Inc , Vanguard Group Inc , Revance Therapeutics Company Profile , Legato Capital Management , Revance Therapeutics , Get Free Report , Marketbeat Ratings , Dwight Moxie , Exchange Commission , Capital Management , Financial Group , Get Free , Revance Therapeutics Daily ,